Is anti‐hbc IgM a useful clinical test in patients with HBsAg‐positive chronic hepatitis or primary hepatocellular carcinoma?
Min Chan Lai, Myron J. Tong, Marek J. Nowicki, Shou‐Dong Lee – 1 May 1988 – Seventy HBsAg‐positive patients, including 24 with primary hepatocellular carcinoma, 34 with chronic active hepatitis, 12 with chronic persistent hepatitis and 30 asymptomatic healthy hepatitis B virus carriers were tested for anti‐HBc IgM using the Corzyme‐M test. Anti‐HBc IgM was detected in 50% of the primary hepatocellular carcinoma patients, 26.5% of the chronic active hepatitis patients, 25% of the chronic persistent hepatitis patients, but in none of the healthy hepatitis B virus carriers.